



Date March 19, 2020
To Paramedics and Paramedic Services within SWORBHP Region
From Southwest Ontario Regional Base Hospital Program
(SWORBHP)
Subject Bronchoconstriction Medical Directive Nebulized Salbutamol

4056 Meadowbrook Drive, unit 145
London, Ontario, Canada N6L 1E5
Phone: (519) 667-6718
Fax: (519) 652-2051
<http://www.lhsc.on.ca>

Effective immediately:

Salbutamol should NOT be administered via the nebulized route.

Given the current COVID-19 global pandemic, there is a need to reduce the risk to health care workers (HCWs) from interventions that may result in the aerosolization of viral particles.

The Bronchoconstriction Medical Directive clinical considerations state that "nebulization is contraindicated in patients with a known or suspected fever or **in the setting of a declared febrile respiratory illness outbreak** by the local medical officer of health". Given the current global pandemic, SWORBHP has made the decision that the current situation qualifies.

Effective immediately and until further notice, the only method by which salbutamol should be administered is via MDI.

Please remember to clearly document clinical situations whereby salbutamol cannot be administered via the MDI route

Matthew Davis, MD, MSc, FRCPC
Regional Medical Director
SWORBHP